Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Spyre Therapeutics ( (SYRE) ) has shared an update.
On April 13, 2026, Spyre Therapeutics suspended and terminated its at-the-market prospectus for the sale of common stock under a previously established Sales Agreement with TD Securities (USA) LLC. As a result, the company halted ATM equity sales until a new offering document is filed, while keeping the underlying Sales Agreement in place, signaling a pause in this specific capital-raising mechanism without fully abandoning the program infrastructure.
This move affects Spyre Therapeutics’ near-term financing flexibility, as it can no longer tap the market through this ATM structure unless it launches a new prospectus or related registration filing. However, by leaving the Sales Agreement intact, the company preserves the option to quickly resume at-the-market offerings in the future, which may be relevant for investors tracking its funding strategy and liquidity planning.
The most recent analyst rating on (SYRE) stock is a Buy with a $64.00 price target. To see the full list of analyst forecasts on Spyre Therapeutics stock, see the SYRE Stock Forecast page.
Spark’s Take on SYRE Stock
According to Spark, TipRanks’ AI Analyst, SYRE is a Neutral.
The score is held back primarily by weak financial performance (no meaningful revenue, large losses, and significant cash burn), partially mitigated by a strong, debt-free balance sheet. Offsetting these risks are strong technical momentum and a notable positive clinical trial event, while valuation remains unattractive due to ongoing losses and no dividend support.
To see Spark’s full report on SYRE stock, click here.
More about Spyre Therapeutics
Spyre Therapeutics operates in the biopharmaceutical industry and is focused on developing and commercializing therapeutic products. The company’s primary activities center on raising capital through equity offerings to support its research, development, and corporate operations, targeting investors in the healthcare and life sciences markets.
Average Trading Volume: 746,796
Technical Sentiment Signal: Buy
Current Market Cap: $4.03B
Learn more about SYRE stock on TipRanks’ Stock Analysis page.